Comparison of rifampicin and moxifloxacin efficacy in an experimental model of animal brucellosis

Journal of Chemotherapy

Volumn 20, Issue 1, 2008, Pages 58-62

  Sezak, Nurbanu ^a   Kuruuzum, Z ^a   Cakir, N ^a   Yuce, A ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Animal; Brucellosis; Experimental; Moxifloxacin; Rifampicin; Treatment

Indexed keywords

MOXIFLOXACIN; RIFAMPICIN; TAP WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CULTURE; BRUCELLA ABORTUS; BRUCELLOSIS; CONTROLLED STUDY; DRUG EFFICACY; LIVER CELL CULTURE; MONOTHERAPY; NONHUMAN; RAT; SPLEEN;

EID: 41149169717     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.1.58     Document Type: Article

References (25)

1. Hall WH. Modern chemotherapy for brucellosis in humans. Rev Infect Dis. 1990;12:1060-99.
2. Young EJ. Brucella species. In: Mandell GL, Bennet JE, Dolin R, eds, Principles and Practice of Infectious Diseases, 4th edn. New York: Churchill Livingstone; 2000: 2386-93.
3. Arda B, Tuncel M, Yaimazhan T, Gokengin D, Gurel O. Efficacy of oral levofloxacin and dirithromycin alone and in combination with rifampicin in the treatment of experimental murine Brucella abortus infection. Int J Antimicrob Agents. 2004;23:204-7.
4. Geyik MF, Dikici B, Kokoglu OF, Bosnak M, Celen MK, Hosoglu S, Ayaz C. Therapeutic effect of spiramycin in brucellosis. Pediatr Int. 2003;45:31-4.
5. Shasha B, Lang R, Rubinstein E. Therapy of experimental murine brucellosis with streptomycin, co-trimoxazole, ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin. Antimicrob Agents Chemother. 1992;36:973-6.
6. Shasha B, Lang R, Rubinstein E. Efficacy of combinations of doxycycline and rifampicin in the therapy of experimental mouse brucellosis. J Antimicrob Chemother. 1994;33:545-51.
7. Lang R, Shasha B, Rubinstein E. Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin. Antimicrob Agents Chemother. 1993 ;37:2333-6.
8. Yumuk Z, Dundar V. The effect of long-term ethanol feeding on efficacy of doxycycline plus rifampicin in the treatment of experimental brucellosis caused by Brucella melitensis in rats. J Chemother. 2005;17:509-13.
9. Siefert HM, Domdey-Bette A, Henninger K, Hucke F. Kohlsdorfer C, Stass HH. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother 1999; 43 (suppl):69-76.
10. Agalar C, Usubutun S, Turkyilmaz R. Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis. Eur J Clin Microbiol Infect Dis. 1999;18:535-8.
11. World Health Organization, Joint FAO/WHO Expert Committee on Brucellosis (Sixth report). 1986: Genova.
12. Ariza J, Gudiol F, Pallares R, Viladrich PF, Rufi G, Corredoira J, Miravitlles MR. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med 1992;117:25-30.
13. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994; 33:685-706.
14. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs. 2002;62:13-59.
15. Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000;59:115-39.
16. Leblebicio lu H, Akova M. Moxifloxacin. Flora, 2002; (suppl).
17. Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother. 2000;46 (suppl): 17-24.
18. Trujillano-Martin I, Garcia-Sanchez E, Martinez IM, Fresnadillo MJ, Garcia-Sanchez JE, Garcia-Rodriguez JA. In vitro activities of six new fluoroquinolones against Brucella melitensis. Antimicrob Agents Chemother. 1999;43:194-5.
19. Kocagoz S, Akova M, Altun B, Gur D, Hascelik G. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. Clin Microbiol Infect. 2002;8:240-2.
20. Rubinstein E, Lang R, Shasha B, Hagar B, Diamanstein L, Joseph G, et al. In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother. 1991;35:1925-7.
21. Akova M, Gur D, Livermore DM, Kocagoz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother. 1999;43:1298-300.
22. al-Sibai MB, Halim MA, el-Shaker MM, Khan BA, Qadri SM. Efficacy of ciprofloxacin for treatment of Brucella melitensis infections. Antimicrob Agents Chemother. 1992;36:150-2.
23. Akova M, Uzun O, Akalin HE, Hayran M, Unal S, Gur D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother. 1993;37:1831-4.
24. Falagas ME, Bliziotis IA. Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimicrob Agents Chemother. 2006;50:22-33.
25. Pappas G, Solera J, Akritidis N, Tsianos E. New approaches to the antibiotic treatment of brucellosis. Int J Antimicrob Agents. 2005;26:101-5.